Approved Anti-Obesity Medications in 2022 KSSO Guidelines and the Promise of Phase 3 Clinical Trials: Anti-Obesity Drugs in the Sky and on the Horizon
Open accessThe DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Abstract
Obesity is a prevalent global health issue affecting approximately half of the world's population.Extensive scientific research highlights the urgent need for effective obesity management to mitigate health risks and prevent complications.While bariatric surgery has proven to be highly effective, providing substantial short-term and long-term weight loss and resolution of obesity-related comorbidities, it is important to recognize its limitations and associated risks.Given the global obesity epidemic and the limitations of surgical interventions, there is high demand for effective and safe anti-obesity medications (AOMs).In Korea, the Korean Society for the Study of Obesity strongly advocates for the use of pharmacotherapy in Korean adults with a body mass index of 25 kg/m² or higher who have not achieved weight reduction through non-pharmacological treatments.Currently, five AOMs have been approved for long-term weight management: orlistat, naltrexone/bupropion, phentermine/topiramate, liraglutide, and semaglutide.Tirzepatide is awaiting approval, and compounds such as CagriSema (Novo Nordisk) and oral semaglutide are currently undergoing rigorous evaluation in phase 3 clinical trials.Furthermore, other promising drugs, including orforglipron, BI 456906, and retartrutide, are progressing to phase 3 studies, expanding the therapeutic options for obesity management.In personalized patient care, physicians play a crucial role in accurately identifying individuals who genuinely require pharmacotherapy and selecting appropriate AOMs based on individual patient characteristics.By integrating evidence-based interventions and considering the unique needs of patients, healthcare professionals significantly contribute to the success of obesity management strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 3 The percentage of participants achieving ≥ 5%, ≥ 10%, ≥ 15%, and ≥ 20% weight loss for each medication. Data were extracted from the following trials: XENical in the Prevention of Diabetes in Obese Subjects (XENDOS; orlistat),8 Contrave Obesity Research I (COR-I; naltrexone/bupropion [NB] extended-release [ER]),23 Satiety and Clinical Adiposity-Liraglutide (SCALE) Obesity and Prediabetes and its extension (liraglutide 3.0 mg),37,40 EQUIP (phentermine/topiramate [P/T] ER 1 year),49 SEQUEL (P/T ER 2 years),31 Semaglutide Treatment Effect in People with obesity (STEP) 1 (semaglutide 2.4 mg),13 and SURMOUNT-1 (tirzepatide 15 mg).48](https://figures.cochat.ai/paper-figures/506dbdfc48e84bddbe64b4302c180eb6/approved-anti-obesity-medications-in-2022-ksso-guidelines-and-the-promise-of-figure-3.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several anti-obesity medications have been approved by the U.S. Food and Drug Administration (FDA), including orlistat, phentermine-topiramate, naltrexone-bupropion, liraglutide, semaglutide, and tirzepatide, while newer agents such as orforglipron and retatrutide continue to emerge through late-phase trials [2,3,4,5,6,7].”
From Gastrointestinal Adverse Effects of Anti-Obesity Medications in Non-Diabetic Adults: A Systematic Review (2025) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Orlistat was consistently associated with oily stools, fecal urgency, and flatulence with discharge, occurring in 15–30% of users [2,5,20]; fat soluble vitamin malabsorption and rare cases of gallstones, kidney stones, liver injury, and pancreatitis were noted as well.”
From Gastrointestinal Adverse Effects of Anti-Obesity Medications in Non-Diabetic Adults: A Systematic Review (2025) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Sympathomimetic agents such as phentermine and combinations like phentermine/topiramate or naltrexone/bupropion, produced fewer GI events overall.”
From Gastrointestinal Adverse Effects of Anti-Obesity Medications in Non-Diabetic Adults: A Systematic Review (2025) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The most common effects were mild constipation, dry mouth, or dysgeusia [2,3,5].”
From Gastrointestinal Adverse Effects of Anti-Obesity Medications in Non-Diabetic Adults: A Systematic Review (2025) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Orlistat causes mechanism-specific adverse effects including steatorrhea, fecal urgency, and oily stools, due to fat malabsorption [2,5].”
From Gastrointestinal Adverse Effects of Anti-Obesity Medications in Non-Diabetic Adults: A Systematic Review (2025) · cites this paper as [5]
Experimental — accuracy not yet measured
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.004 · Cited by 4,058
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
European Guidelines for Obesity Management in Adults
Yumuk, V., Tsigos, C., Fried, M., Schindler, K., Busetto, L., Micic, D., & Toplak, H. (2015) · Obesity Facts · doi:10.1159/000442721 · Cited by 3,432
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437739.71477.ee · Cited by 2,735
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724 · cited 2×
“Liraglutide shares a 97% amino acid sequence similarity with human GLP-1(7-37), with the substitution of lysine to arginine at position 34, and it also has palmitic acid conjugated via a glutamate spacer at lysine in position 26.”
BackgroundMechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170 · cited 2×
“Liraglutide shares a 97% amino acid sequence similarity with human GLP-1(7-37), with the substitution of lysine to arginine at position 34, and it also has palmitic acid conjugated via a glutamate spacer at lysine in position 26.”
BackgroundFuller, N. R., Colagiuri, S., Schofield, D., Olson, A. D., Shrestha, R., Holzapfel, C., Wolfenstetter, S. B., Holle, R., Ahern, A. L., Hauner, H., et al. (2013) · International Journal of Obesity · doi:10.1038/ijo.2012.139 · Cited by 2,117
A Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028395 · Cited by 2,039
XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study
Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.155 · Cited by 1,915
Cited by
McGowan, B., Ciudin, A., Baker, J. L., Busetto, L., Dicker, D., Frühbeck, G., Goossens, G. H., Monami, M., Sbraccia, P., Martinez-Tellez, B., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03978-z · Cited by 100
“Current guidelines recommend that, particularly for high-risk people with severe obesity or obesity-related complications, lifestyle programs can be combined with OMMs or metabolic bariatric surgery (MBS) 10–13 , with recent evidence suggesting that these interventions can be risk stratified 14,15 .”
Subramaniyan, V., & Hanim, Y. U. (2025) · International Journal of Obesity · doi:10.1038/s41366-025-01729-1 · Cited by 112
“However, when employing strategy-related pharma-cotherapy for obesity management, scientists and healthcare providers should adhere to several core guidelines [86].”
Pan, X., Tan, B., Chin, Y. H., Lee, E. C. Z., Kong, G., Chong, B., Kueh, M., Khoo, C. M., Mehta, A., Majety, P., et al. (2024) · Obesity · doi:10.1002/oby.24002 · Cited by 71
“Other studies have also reported similar results in which tirzepatide improved metabolic conditions of patients with mild to moderate adverse effects [76].”
ResultXie, Z., Zheng, G., Liang, Z., Li, M., Deng, W., & Cao, W. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156038 · Cited by 54
GLP-1 Receptor Agonists in Idiopathic Intracranial Hypertension
Sioutas, G. S., Mualem, W., Reavey-Cantwell, J. F., & Rivet, D. J. (2025) · JAMA Neurology · doi:10.1001/jamaneurol.2025.2020 · Cited by 60
The promise of tirzepatide: A narrative review of metabolic benefits
Sokary, S., & Bawadi, H. A. (2025) · Primary care diabetes · doi:10.1016/j.pcd.2025.03.008 · Cited by 44
Kansakar, U., Jankauskas, S. S., Pande, S., Mone, P., Varzideh, F., & Santulli, G. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27031409 · Cited by 22
Kanai, R., Kinoshita, S., Kanbe, I., Sameda, M., Yamaoka, S., Horikawa, O., Watanabe, Y., Tatsuno, I., Shirai, K., Oshiro, T., et al. (2024) · Obesity Pillars · doi:10.1016/j.obpill.2023.100098 · Cited by 31
Embracing the Pros and Cons of the New Weight Loss Medications (Semaglutide, Tirzepatide, Etc.)
Moyad, M. A. (2023) · Current Urology Reports · doi:10.1007/s11934-023-01180-7 · Cited by 21
Luca, M. D., Belluzzi, A., Salminen, P. T. P., Bueter, M., Pujol‐Rafols, J., Sakran, N., Stier, C. K., Taşkın, H. E., Chiappetta, S., Carrano, F. M., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13175106 · Cited by 17
Bariatric surgery for treatment of morbid obesity in adults
Park, K. B., & Jun, K. (2024) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2024.219 · Cited by 19
“Dual GIP/GLP-1 receptor agonists combine the effects of GIP and GLP-1 to improve blood glucose control and suppress appetite [103].”
InfluentialCheah, S.-Y., Phang, Y.-K., Lim, S. C.-Y., Koh, M.-X., Djearamane, S., Subramaniam, H., Lim, B. H., Li, F., Aminuzzaman, M., Wong, L. S., et al. (2026) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2026.2668258 · Cited by 16
Takrori, E., Peshin, S., & Singal, S. (2025) · Medicina · doi:10.3390/medicina61111987 · Cited by 13
“Sympathomimetic and combination agents induce modest constipation or nausea through central norepinephrine and dopamine modulation that alters intestinal tone [3,5].”
InfluentialKwon, E.-Y., Kim, J., Choi, J., Hwang, K., & Han, Y. (2025) · Food Science & Nutrition · doi:10.1002/fsn3.70655 · Cited by 9
“Sibutramine (an appetite suppressant) and orlistat (a fat absorption inhibitor) have been approved for extended use beyond 3 months in the Korean domestic market (Jeon et al. 2023).”
Old and new anti-obesity drugs
Dodangeh, S., & Hasani‐Ranjbar, S. (2024) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-024-01512-5 · Cited by 8
“These positive outcomes contribute to the potential reduction of obesity-related morbidity and mortality [56].”
Impact of Semaglutide Administration on Weight Loss After Bariatric Surgery: A Meta-Analysis
Jamialahamdi, T., Mirhadi, E., Almahmeed, W. A., Virani, S. S., Eid, A. H., Al‐Rasadi, K., Salehabadi, S., & Sahebkar, A. (2025) · Obesity Surgery · doi:10.1007/s11695-025-07848-y · Cited by 10
“In this context, it is worth noting that sema-glutide promotes weight loss through mechanisms such as delayed gastric emptying and appetite suppression mediated by hypothalamic GLP-1 receptors [24].”
Kim, M.-K., & Kim, H. S. (2024) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2024.228 · Cited by 10
Advances in Incretin‐Based Therapies for MAFLD: Mechanisms and Clinical Evidence
Dong, W., Zhang, H., Mu, S., Shi, S., Zhang, J., & Xu, K. (2025) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.70131 · Cited by 7
“48 Given the extensive distribution of incretin and related hormone receptors in key metabolic organs, such as the pancreas, liver, adipose tissue, and intestines, and their intimate connection with glucolipid metabolic pathways, in-depth analysis of the core mechanisms by which GLP-1R agonists,…”
Common postbariatric surgery emergencies for the acute care surgeon: What you need to know
Cheng, V. C., Samakar, K., Dobrowolsky, A. B., Nguyen, J. D., Abel, S. A., Pakula, A. M., Bernard, A. C., & Martin, M. J. (2023) · The Journal of Trauma: Injury, Infection, and Critical Care · doi:10.1097/ta.0000000000004125 · Cited by 6
Kim, S.-E., & Yoo, B. (2025) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2024.387 · Cited by 5
“Glucagon receptor agonists reduce glucagon release, improve blood sugar levels, reduce food intake, and increase energy expenditure [107].”
Luca, M. D., COHEN, R. V., Belluzzi, A., Navarra, G., Lorenzo, N. D., Petry, T. B. Z., Sbraccia, P., Busetto, L., Buscemi, S., Barazzoni, R., et al. (2026) · Obesity · doi:10.1002/oby.70083 · Cited by 5
Ahmed, I. S., Tapponi, S. L., Manaa, H. M., Soltani, A., Hussein, E. S., Parvaresh, F. A., & Hussain, Z. (2026) · Journal of Obesity · doi:10.1155/jobe/6556057 · Cited by 5
Lyu, Y. S., Ahn, H. Y., Hong, S., & Park, C. (2024) · Drug Design Development and Therapy · doi:10.2147/dddt.s492913 · Cited by 7
“10 11–13 Despite the promising outcomes observed in randomized controlled trials (RCTs) and meta-analysis, 9,11–14 post-marketing surveillance is imperative for assessing the real-world effectiveness and safety profile of naltrexone-bupropion therapy.”
Obesity epidemic in European countries: from an unaddressed risk factor to a medicalized disease?
Garattini, L., & Fattore, G. (2024) · The European Journal of Health Economics · doi:10.1007/s10198-024-01752-5 · Cited by 2
Moxó, J. S., Fonseca, A. C., Matos, G., Saraiva, J. A., Pereira, R., Rocha, C., Vasconcelos, V. M., & Urbatzka, R. (2025) · Algal Research · doi:10.1016/j.algal.2025.104003 · Cited by 3
Mukherjee, S., Skrede, S., & Fernø, J. (2025) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-025-10009-2 · Cited by 2
“However, it was not until 2021 that semaglutide was offi - cially approved as a treatment for obesity [ 110].”
Strategies for Long-Term Weight Loss and Maintenance
Seo, Y. B. (2023) · Korean Journal of Family Practice · doi:10.21215/kjfp.2023.13.3.128 · Cited by 2
The Transformative Impact of New Anti-Obesity Medications: A Paradigm Shift in Medical Practice?
Sharma, A. M. (2023) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes23078 · Cited by 3
“As outlined in the recent article by Jeon et al. 3 on the obesity pharmacotherapy guidelines recommended by the Korean Society for the Study of Obesity (KSSO), pharmacotherapy is strongly recommended by the KSSO for Korean adults with a body mass index of 25 kg/m 2 or higher who have not achieved…”
BackgroundMultifrequency low-level laser-assisted lipolysis outcomes. A dataset from 101 patients
Cubillos-Valencia, G., Vasquez, N., Pulido, A. M. O., Rivera-Porras, D., & Bermúdez, V. (2024) · Data in Brief · doi:10.1016/j.dib.2024.111038 · Cited by 2
Yokote, K., Ota, R., Wada, S., Matsuda, H., & Filomeno, R. (2024) · Advances in Therapy · doi:10.1007/s12325-024-02941-7 · Cited by 7
“In South Korea, several AOMs are approved for weight management, with others in phase 3 trials [13], but, in China, few medications have been approved and there is a need for robust clinical trials to inform treat-ment guidelines [14].”
BackgroundPanchal, A., & Khantal, A. (2024) · Research Journal of Pharmacology and Pharmacodynamics · doi:10.52711/2321-5836.2024.00020 · Cited by 1
Efficacy and Safety of Tirzepatide and Semaglutide for Obesity Management: A Real-World Comparison
Shil, K. K., Hira, A. D., Bakchi, S., Paul, S., Hossain, M., & Ghosh, D. K. (2025) · Cureus · doi:10.7759/cureus.98858 · Cited by 6
“…like tirzepatide, in managing obesity presents a significant advancement in pharmacotherapy, offering healthcare professionals new tools in combating obesity-related health complications in developing countries like Bangladesh, where original molecules are unavailable and also costly [11].”
Choi, W.-S., Song, M.-K., Seo, M. W., Woo, Y. S., & Bahk, W. (2026) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253261419609 · Cited by 2
Guidelines for obesity clinic consultations in primary healthcare clinics
Kang, J., & Kim, K. K. (2024) · Journal of Korean Medical Association · doi:10.5124/jkma.2024.67.4.240 · Cited by 3
Self-citationFood Bioactives in the Prevention and Clinical Management of Obesity
Laya, A., Carvalho, E., Fernandes, I., Oliveira, J., Siewe, F. B., Wangso, H., & Djakba, R. (2025) · Springer eBooks · doi:10.1007/978-981-97-9723-3_13 · Cited by 1
Hocaoğlu-Emre, F. S. (2023) · International Conference on Recent Academic Studies · doi:10.59287/as-proceedings.114
NEW TREATMENTS FOR OBESITY: DOUBLE AGONIST TWO GIP/ GLP-1 RECEPTORS – TIRZEPATIDE
Pinto, G. M., Gonçalves, M. C., Duarte, P. L. S., Mendes, E. A. B. N., Massariol, L. B., Navarro, M. P. T. B. D. M., Burnier, V. D. L., Rosa, J. D. A. A., Fonseca, L. C., Carbone, M., et al. (2024) · International Journal of Health Science · doi:10.22533/at.ed.1594122423011
Lee, M., Park, S., Park, S., Park, H., Lee, Y. R., Kim, M.-S., Nam, M., Lee, J., Seo, H., Lee, Y., et al. (2025) · Clinical Hypertension · doi:10.5646/ch.2025.31.e28 · Cited by 1
“In addition, some individuals with obesity may pursue active weight reduction with the use of anti-obesity medications, such as orlistat, naltrexone/bupropion, phentermine/topiramate, liraglutide, and semaglutide [43].”
Figueroa-Guzmán, C., Gaona-García, R. Y., Campos-Morales, M. E., Martínez-Alcantar, L., & Campos-García, J. (2026) · Journal of physiology and biochemistry · doi:10.1007/s13105-026-01223-w
Metadata
- Authors
- Jeon, E., Lee, K. Y., & Kim, K.-K.
- Affiliations
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Daegu Catholic University School of Medicine, Daegu, Korea
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Gachon University College of Medicine, Incheon, Korea
- Gachon University (KR)
- Corresponding author
- Kim, Kyoung-Kon
- Venue
- Journal of Obesity & Metabolic Syndrome
- Published
- 2023-06-23
- Volume
- 32
- Issue
- 2
- Pages
- 106-120
- ISSN
- 2508-6235 (ISSN-L)
- 2508-7576
- PMC
- PMC10327684
- OpenAlex
- W4381610885
- Cited by
- 39
- References
- 69
- Citations by year
- 2026: 6 · 2025: 14 · 2024: 14 · 2023: 5
- FWCI
- 1.42
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0/ (tdm)
- Locations
- Journal of Obesity & Metabolic Syndrome (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
- Keywords
- anti-obesity drugs, obesity pharmacotherapy, orlistat, naltrexone/bupropion, phentermine/topiramate, liraglutide, semaglutide, tirzepatide, orforglipron, obesity treatment, drug approval
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.